Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs. It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial. Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284 which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively. Early-stage work emphasizes ADCs and orphan indications. STAR-001 is the lead candidate for Starlight Therapeutics, Lantern's CNS-focused subsidiary. Lantern uses AI & machine learning to rescue failed & abandoned compounds by predicting response in biomarker-defined subpopulations. RADR is the firm's AI platform which analyzes proprietary, curated data to identify new candidates, mechanisms of action & patients most likely to respond to drug therapy, de-risking clinical trials to save time & cost. Lantern launched its Ph2 trial for LP-300 in never-smoker NSCLC in late 2022. We expect it to lead into a Ph3 study that will generate registrational data followed by US & EU regulatory submission & commercialization. LP-184 is undergoing clinical trials in defined advanced tumors while LP-284 has been cleared for human trials.
14 May 2024
LTRN: Expanding Horizons into Asia
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
LTRN: Expanding Horizons into Asia
Lantern Pharma, Inc. (LTRN:NAS) | 0 0 0.0%
- Published:
14 May 2024 -
Author:
John Vandermosten -
Pages:
10
Lantern Pharma uses AI & data to identify drug responders, uncover mechanism of action & rescue failed drugs. It is developing LP-300 for non- & never smoker NSCLC in the Harmonic trial. Secondary candidates include LP-100 for mCRPC and LP-184 and LP-284 which are in clinical development for multiple biomarker-defined tumors and hematological cancers, respectively. Early-stage work emphasizes ADCs and orphan indications. STAR-001 is the lead candidate for Starlight Therapeutics, Lantern's CNS-focused subsidiary. Lantern uses AI & machine learning to rescue failed & abandoned compounds by predicting response in biomarker-defined subpopulations. RADR is the firm's AI platform which analyzes proprietary, curated data to identify new candidates, mechanisms of action & patients most likely to respond to drug therapy, de-risking clinical trials to save time & cost. Lantern launched its Ph2 trial for LP-300 in never-smoker NSCLC in late 2022. We expect it to lead into a Ph3 study that will generate registrational data followed by US & EU regulatory submission & commercialization. LP-184 is undergoing clinical trials in defined advanced tumors while LP-284 has been cleared for human trials.